Since the PD-1 signal can be exploited by tumor cells to evade an anti-cancer immune response, the PD-L1/PDL-1 pathway is the most broadly studied immune checkpoint in cancer, including urothelial cancer [14]. Here, PDCD1 is linked to cancer.